help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hensleigh, P. A.
Right arrow Articles by Grotjan HE, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hensleigh, P. A.
Right arrow Articles by Grotjan HE, J. R.

Journal of Clinical Endocrinology & Metabolism, Vol 40, 816-823, Copyright © 1975 by Endocrine Society

ARTICLES

Fetal protection against masculinization with hyperreactio luteinalis and virilization

PA Hensleigh, RP Carter and JR Grotjan HE

In a unique patient with secondary amenorrhea and hirsutism prior to pregnancy, lutein cysts with hyperreactio luteinalis enlarged the ovaries to a diameter of 25 cm during pregnancy. The purpose of the study was to explore the possibility that placental aromatization of androgens may be a metabolic barrier that offers protection against masculinization of a female fetus. Maternal serum, umbilical cord serum and lutein cyst fluid were analyzed for testosterone, progesterone and estradiol content. The cardinal clinical findings were marked maternal virilization but no fetal masculinization. At the time of delivery, massive ovarian production of testosterone and a large maternal-fetal testosterone gradient were found. The maternal arm vein testosterone level, 15,000 ng/dl, was about 100 times normal level, the material ovarian vein level was 51,800 ng/dl, while the cord blood level was only 465 ng/dl. At the same time there was an increase in fetal cord blood estradiol to 33 ng/ml, a 7-fold increase compared to normal cord levels. A protective mechanism for the fetus may exist when maternal androgens are markedly elevated due to a maternal endocrinopathy concurrent with pregnancy. Our data are compatible with the concept that placental aromatization of androgens may function as a metabolic barrier, thus offering protection to the fetus from excessive maternal androgens. Another facet of the protective mechanism may be increased fetal exposure to potent estrogens, which may buffer the influence of androgens reaching the fetus.


This article has been cited by other articles:


Home page
 Hum ReprodHome page
T. Sir-Petermann, M. Maliqueo, B. Angel, H.E. Lara, F. Perez-Bravo, and S.E. Recabarren
Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization
Hum. Reprod., October 1, 2002; 17(10): 2573 - 2579.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
V. Mazza, I. Di Monte, P.L. Ceccarelli, F. Rivasi, C. Falcinelli, A. Forabosco, and A. Volpe
Prenatal diagnosis of female pseudohermaphroditism associated with bilateral luteoma of pregnancy: Case report
Hum. Reprod., March 1, 2002; 17(3): 821 - 824.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. C. Lo, V. M. Schwitzgebel, J. B. Tyrrell, P. A. Fitzgerald, S. L. Kaplan, F. A. Conte, and M. M. Grumbach
Normal Female Infants Born of Mothers with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency
J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 930 - 936.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1975 by The Endocrine Society